Atossa Therapeutics Common Stock to Begin Trading with Stapled Contingent Value Rights After Close of Business Today
Atossa Therapeutics confirmed that each outstanding share of its common stock begins trading with one stapled contingent value right as of the close of business on October 19, 2026. Each CVR entitles holders to 25% of net proceeds from the sale or deemed monetization of Atossa's first qualifying priority review voucher, capped at $50 million in aggregate, with an outside date of December 31, 2036. Shares issued after the record date will also carry an attached CVR until detachment or expiration. The CVRs are highly contingent: no Atossa product is FDA-approved, no marketing application has been submitted for (Z)-endoxifen in DMD or McCune-Albright syndrome, and no PRV has been awarded.
Key figures
- Record date
- October 19, 2026
- Cvr outside date
- December 31, 2036
- Cvr participation
- 25% of net proceeds from sale or deemed monetization of first qualifying PRV
- Cvr payment cap usd
- 50000000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.